MisterBlues schreef op 19 augustus 2020 23:28:
Van YF, een zekere Michael over de geschiedenis van Aviptadil en de vele mogelijke toepassingen:
FDA approval is coming for these reasons: 1. It works, according to latest clinical studies (thanks @chartgirl72 for the early news). 2. Safety profile is well documented for over 30 years so there's no reason not to approve it since the efficacy in early scientific studies is more than impressive. 3. NueroRx went out of their way to trademark it SAMIVIR and SAMIVIP in honor of their late colleague and the scientist who co-discovered VIP, Sami Said MD (RIP 2013). Dr. Said's dream was to see VIP save lives as a commercial therapy. I don't think his peers would name it after him unless this dream was going to be realized in a big way (a bit of a stretch I know, but it's quite the post-humous honor right?). Furthermore, I've read vasoactive intestinal peptide studies all the way back to 1989. VIP is stable as a synthetic peptide in the form of Aviptadil (SAMIVIR is a cooler name too). After FDA approval this may even help with asthma in inhaled form. That's big time. (In the past peptidases broke down natural VIP too fast for much therapy to be realized but now that it is in stable form as a synthetic peptide, it opens up multiple revenue streams for tx including pulmonary fibrosis, sarcoidosis, asthma (maybe), ED (for sure), Weight loss, and how do I put this politely... vaginal lubrication. (Sorry, that's the medical term).
Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with Asthma: www.nejm.org/doi/10.1056/NEJM19890511...